A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY
Simple Summary
- Supplementary File 1:
ZIP-Document (ZIP, 344 KiB)
Kim, J.H.; Yoo, C.; Seo, S.; Jeong, J.H.; Ryoo, B.-Y.; Kim, K.-p.; Lee, J.B.; Lee, K.-W.; Kim, J.-W.; Kim, I.-H.; Kang, M.; Ryu, H.; Cheon, J.; Park, S.R. A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. Cancers 2022, 14, 559. https://doi.org/10.3390/cancers14030559
Kim JH, Yoo C, Seo S, Jeong JH, Ryoo B-Y, Kim K-p, Lee JB, Lee K-W, Kim J-W, Kim I-H, Kang M, Ryu H, Cheon J, Park SR. A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. Cancers. 2022; 14(3):559. https://doi.org/10.3390/cancers14030559
Chicago/Turabian StyleKim, Jwa H., Changhoon Yoo, Seyoung Seo, Jae H. Jeong, Baek-Yeol Ryoo, Kyu-pyo Kim, Jung B. Lee, Keun-Wook Lee, Ji-Won Kim, Il-Hwan Kim, Myoungjoo Kang, Hyewon Ryu, Jaekyung Cheon, and Sook R. Park. 2022. "A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY" Cancers 14, no. 3: 559. https://doi.org/10.3390/cancers14030559